These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23229621)

  • 1. Fotemustine-related leukoencephalopathy.
    Renard D; Stoebner P; Campello C; Meunier L
    Acta Neurol Belg; 2013 Sep; 113(3):365-6. PubMed ID: 23229621
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
    Gill S; Shapiro J; Westerman D; Prince HM
    J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
    [No Abstract]   [Full Text] [Related]  

  • 3. Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Turrisi G; Sozzi P; Marinozzi C; Clerico MA
    Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological toxicity during metastatic melanoma treatment with fotemustine.
    Khalil Z; Pageot N; Carlander B; Guillot B
    Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A probable mechanism for hyperpigmentation by fotemustine.
    Schallreuter KU; Ring J
    Dermatology; 1992; 185(1):76-7. PubMed ID: 1638080
    [No Abstract]   [Full Text] [Related]  

  • 6. [New toxicity of fotemustine: diffuse interstitial lung disease].
    Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
    Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
    Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
    Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fotemustine: muphoran].
    Avril MF
    Ann Dermatol Venereol; 2007 Dec; 134(12):997-1000. PubMed ID: 18166925
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
    Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
    [No Abstract]   [Full Text] [Related]  

  • 10. Fotemustine in the treatment of brain primary tumors and metastases.
    Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
    Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
    Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
    Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
    Mangiacavalli S; Pica G; Varettoni M; Lazzarino M; Corso A
    Eur J Haematol; 2009 Mar; 82(3):240-1. PubMed ID: 19018860
    [No Abstract]   [Full Text] [Related]  

  • 13. Prevention of hepatotoxicity but loss of antimelanoma effect with combined fotemustine and anti-oxidant treatment.
    Webster GJ; Kurtovic J; Singh-Grewal I; Friedlander M; Riordan SM
    Intern Med J; 2004 May; 34(5):298-9. PubMed ID: 15151681
    [No Abstract]   [Full Text] [Related]  

  • 14. Fotemustine for the treatment of melanoma.
    Quéreux G; Dréno B
    Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
    Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
    J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic uveal melanoma with intravenous fotemustine.
    Spagnolo F; Grosso M; Picasso V; Tornari E; Pesce M; Queirolo P
    Melanoma Res; 2013 Jun; 23(3):196-8. PubMed ID: 23624366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serpentine supravenous hyperpigmentation induced by the nitrosourea fotemustine.
    Claudy AL; Lévigne V; Boucheron S
    Dermatology; 1992; 184(1):70-2. PubMed ID: 1559000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant intra-arterial hepatic fotemustine for high-risk uveal melanoma patients.
    Voelter V; Schalenbourg A; Pampallona S; Peters S; Halkic N; Denys A; Goitein G; Zografos L; Leyvraz S
    Melanoma Res; 2008 Jun; 18(3):220-4. PubMed ID: 18477897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Logistic regression model of fotemustine toxicity combining independent phase II studies.
    Raymond E; Haon C; Boaziz C; Coste M
    Cancer; 1996 Nov; 78(9):1980-7. PubMed ID: 8909320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation.
    Gruss C; Geissler A; Schalke B; Landthaler M; Stolz W
    Melanoma Res; 2002 Aug; 12(4):403-4. PubMed ID: 12170192
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.